 John Montford
Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ureteral Obstruction | 3 | 2021 | 64 | 1.370 |
Why?
| | Group IV Phospholipases A2 | 2 | 2017 | 47 | 1.070 |
Why?
| | Acute Kidney Injury | 6 | 2024 | 809 | 1.020 |
Why?
| | Kidney | 4 | 2022 | 1467 | 0.950 |
Why?
| | Lipoxygenase Inhibitors | 2 | 2021 | 37 | 0.790 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2021 | 18 | 0.750 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2021 | 23 | 0.740 |
Why?
| | Nephritis | 1 | 2021 | 22 | 0.740 |
Why?
| | Kidney Tubules | 2 | 2019 | 117 | 0.630 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2024 | 612 | 0.610 |
Why?
| | Inflammation Mediators | 1 | 2021 | 513 | 0.600 |
Why?
| | Metabolome | 1 | 2021 | 350 | 0.580 |
Why?
| | Connective Tissue Growth Factor | 1 | 2017 | 25 | 0.560 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2017 | 17 | 0.560 |
Why?
| | Sepsis | 1 | 2024 | 614 | 0.550 |
Why?
| | Hyperkalemia | 1 | 2017 | 24 | 0.540 |
Why?
| | Fibrosis | 5 | 2021 | 552 | 0.530 |
Why?
| | Kidney Diseases | 2 | 2017 | 407 | 0.520 |
Why?
| | Cell Dedifferentiation | 1 | 2016 | 32 | 0.520 |
Why?
| | Bone Marrow | 1 | 2017 | 286 | 0.500 |
Why?
| | Energy Metabolism | 1 | 2021 | 919 | 0.480 |
Why?
| | Reperfusion Injury | 3 | 2023 | 279 | 0.450 |
Why?
| | Cytokines | 1 | 2021 | 2084 | 0.420 |
Why?
| | Fibroblast Growth Factors | 1 | 2013 | 171 | 0.370 |
Why?
| | Dyslipidemias | 1 | 2013 | 176 | 0.350 |
Why?
| | Mice, Inbred C57BL | 6 | 2023 | 5750 | 0.350 |
Why?
| | Epithelial Cells | 1 | 2016 | 1094 | 0.330 |
Why?
| | Renal Dialysis | 1 | 2013 | 435 | 0.300 |
Why?
| | Disease Models, Animal | 6 | 2024 | 4282 | 0.270 |
Why?
| | Kidney Failure, Chronic | 1 | 2013 | 566 | 0.270 |
Why?
| | Body Mass Index | 1 | 2013 | 2375 | 0.220 |
Why?
| | Azotemia | 1 | 2023 | 7 | 0.210 |
Why?
| | Animals | 12 | 2024 | 36850 | 0.210 |
Why?
| | Mice, Knockout | 2 | 2021 | 3009 | 0.200 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 84 | 0.180 |
Why?
| | Phenotype | 2 | 2021 | 3189 | 0.170 |
Why?
| | Leukocytes | 1 | 2021 | 311 | 0.170 |
Why?
| | Lipocalins | 1 | 2019 | 36 | 0.160 |
Why?
| | Mice | 7 | 2023 | 17759 | 0.160 |
Why?
| | Receptors, Leukotriene | 1 | 2019 | 14 | 0.150 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2019 | 43 | 0.150 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2023 | 382 | 0.140 |
Why?
| | Nephrectomy | 1 | 2019 | 168 | 0.140 |
Why?
| | Polycystic Kidney Diseases | 1 | 2019 | 76 | 0.140 |
Why?
| | Lymphangiogenesis | 1 | 2017 | 27 | 0.140 |
Why?
| | Nephrosclerosis | 1 | 2016 | 6 | 0.130 |
Why?
| | Arachidonic Acid | 1 | 2016 | 120 | 0.130 |
Why?
| | Optical Imaging | 1 | 2016 | 61 | 0.120 |
Why?
| | Ischemia | 1 | 2019 | 407 | 0.120 |
Why?
| | Dinoprostone | 1 | 2016 | 191 | 0.120 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2017 | 382 | 0.120 |
Why?
| | Gene Silencing | 1 | 2016 | 195 | 0.120 |
Why?
| | Microscopy, Fluorescence | 1 | 2016 | 397 | 0.110 |
Why?
| | Cadherins | 1 | 2016 | 205 | 0.110 |
Why?
| | Retinoid X Receptors | 1 | 2014 | 39 | 0.110 |
Why?
| | Angiotensin II | 1 | 2014 | 99 | 0.110 |
Why?
| | Macrophages | 1 | 2021 | 1544 | 0.110 |
Why?
| | Glomerular Filtration Rate | 3 | 2023 | 745 | 0.100 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2014 | 261 | 0.100 |
Why?
| | Cholesterol, HDL | 1 | 2013 | 203 | 0.100 |
Why?
| | Promoter Regions, Genetic | 1 | 2016 | 1249 | 0.090 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2014 | 445 | 0.090 |
Why?
| | Lipocalin-2 | 2 | 2023 | 79 | 0.090 |
Why?
| | Critical Illness | 1 | 2017 | 804 | 0.090 |
Why?
| | Cholesterol, LDL | 1 | 2013 | 366 | 0.090 |
Why?
| | Cell Line | 1 | 2016 | 2838 | 0.090 |
Why?
| | Triglycerides | 1 | 2013 | 524 | 0.080 |
Why?
| | Linear Models | 1 | 2013 | 846 | 0.080 |
Why?
| | Humans | 7 | 2024 | 136803 | 0.080 |
Why?
| | Proportional Hazards Models | 1 | 2013 | 1262 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1572 | 0.080 |
Why?
| | Gene Expression | 1 | 2014 | 1500 | 0.080 |
Why?
| | Prognosis | 1 | 2017 | 4013 | 0.070 |
Why?
| | Cell Proliferation | 1 | 2016 | 2476 | 0.070 |
Why?
| | Signal Transduction | 2 | 2019 | 5077 | 0.070 |
Why?
| | Male | 6 | 2023 | 67330 | 0.070 |
Why?
| | Interleukin-6 | 2 | 2023 | 778 | 0.070 |
Why?
| | Culicidae | 1 | 2005 | 37 | 0.060 |
Why?
| | West Nile virus | 1 | 2005 | 43 | 0.060 |
Why?
| | Acute-Phase Reaction | 1 | 2023 | 41 | 0.050 |
Why?
| | Furosemide | 1 | 2023 | 37 | 0.050 |
Why?
| | Inflammation | 1 | 2014 | 2835 | 0.050 |
Why?
| | Cohort Studies | 1 | 2013 | 5704 | 0.050 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5424 | 0.050 |
Why?
| | Animals, Newborn | 1 | 2023 | 844 | 0.040 |
Why?
| | Rats | 2 | 2023 | 5639 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2023 | 543 | 0.040 |
Why?
| | Biomarkers | 2 | 2023 | 4145 | 0.040 |
Why?
| | Acute-Phase Proteins | 1 | 2019 | 67 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2019 | 189 | 0.040 |
Why?
| | Hepatocytes | 1 | 2019 | 220 | 0.040 |
Why?
| | Random Allocation | 1 | 2019 | 353 | 0.040 |
Why?
| | Creatinine | 1 | 2019 | 499 | 0.030 |
Why?
| | Sex Factors | 1 | 2022 | 2064 | 0.030 |
Why?
| | Recovery of Function | 1 | 2019 | 652 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1733 | 0.030 |
Why?
| | Blood Pressure | 1 | 2022 | 1774 | 0.030 |
Why?
| | Liver | 1 | 2023 | 1940 | 0.030 |
Why?
| | Tetrahydronaphthalenes | 1 | 2014 | 29 | 0.030 |
Why?
| | Chemokine CCL2 | 1 | 2014 | 115 | 0.030 |
Why?
| | Microfilament Proteins | 1 | 2014 | 131 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 283 | 0.030 |
Why?
| | PPAR gamma | 1 | 2014 | 182 | 0.030 |
Why?
| | Aged | 1 | 2013 | 23808 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2014 | 218 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 320 | 0.020 |
Why?
| | Actins | 1 | 2014 | 416 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2014 | 437 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2023 | 6032 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2751 | 0.020 |
Why?
| | Middle Aged | 1 | 2013 | 33239 | 0.020 |
Why?
| | Female | 2 | 2022 | 72816 | 0.020 |
Why?
| | Lung | 1 | 2023 | 4063 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2014 | 2486 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 6809 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2014 | 4192 | 0.020 |
Why?
| | Ochlerotatus | 1 | 2005 | 3 | 0.010 |
Why?
| | Encephalitis Virus, St. Louis | 1 | 2005 | 3 | 0.010 |
Why?
| | Culex | 1 | 2005 | 16 | 0.010 |
Why?
| | Texas | 1 | 2005 | 241 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 975 | 0.010 |
Why?
|
|
Montford's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|